EGFR and neoplasm: Given that the broader spectrum of activity and irreversible mechanism of action of afatinib was predicted to result in improved inhibition of EGFR-dependent tumor growth, compared with the first-generation EGFR-TKIs, a randomized, open-label phase IIb trial (LUX-Lung 7) of afatinib versus gefitinib was performed for the first-line treatment of patients with advanced lung adenocarcinoma who were positive for activating mutations (exon-19 deletions or the L858R point mutation) of EGFR [10].